Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 18, 2011 - Issue 4
221
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity

, , &
Pages 222-228 | Received 22 Aug 2011, Accepted 26 Sep 2011, Published online: 02 Nov 2011
 

Abstract

Diabetes in the domestic ferret (Mustela putorius furo) has previously been described and the purpose of this study was to evaluate if the ferret could serve as a model for the study of β-cell degeneration associated with formation of islet amyloid. The nucleotide and amino acid sequence of ferret islet amyloid polypeptide (IAPP) 1–37 was identified and the synthesized peptide was studied with regards to in vitro amyloidogenicity and potential cellular toxicity in a comparative approach to human, cat and the non-amyloidogenic rat IAPP. Ferret IAPP forms amyloid-like fibrils, but with a longer lag phase than human and cat IAPP and the aggregation process was shown to reduce cell viability of cultured β-cells, but with less potency than these two amyloidogenic counterparts. Immunohistochemistry of ferret pancreas confirmed IAPP expression in the islets of Langerhans, but no islet amyloid was found in a very limited sample size of one diabetic and five healthy ferrets. Islet amyloid has never been described in ferrets, and it is not possible to determine if it is due to lack of studies/material or to the fact that the ferret’s life span is too short to present with such pathology.

Acknowledgements

JFP would like to thank Novo Nordisk R&D science talent attraction and recruitment program for the Scandinavian return fellowship and Susanne Juul Rasmussen for tissue embedding and sectioning. The authors wish to thank Dr. Bruce Williams for sharing his experience on pancreas pathology in ferrets.

Declaration of interest: This work was funded by Novo Nordisk A/S. JFP, LS and KD are employed by Novo Nordisk A/S and by this mean the funder played a role in the study design, data collection, decision to publish and preparation of the manuscript. MOBB has no interests to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.